SFA 006
Alternative Names: SFA-006Latest Information Update: 13 Oct 2025
At a glance
- Originator SFA Therapeutics
- Class Anti-infectives; Antivirals
- Mechanism of Action G-protein coupled receptor 43 modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
- Research Cytokine release syndrome; Post acute COVID 19 syndrome; Sepsis
Most Recent Events
- 13 Oct 2025 SFA 006 is still in early research in Cytokine release syndrome in USA (unspecified route) (SFA therapeutics pipeline, October 2025)
- 13 Oct 2025 SFA 006 is still in early research in Post-acute-COVID-19-syndrome in USA (unspecified route) (SFA therapeutics pipeline, October 2025)
- 13 Oct 2025 SFA 006 is still in early research in Sepsis in USA (unspecified route) (SFA therapeutics pipeline, October 2025)